Compare OSPN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | IVVD |
|---|---|---|
| Founded | 1991 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.1M | 437.1M |
| IPO Year | 2000 | 2021 |
| Metric | OSPN | IVVD |
|---|---|---|
| Price | $10.55 | $1.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $16.67 | $8.75 |
| AVG Volume (30 Days) | 550.2K | ★ 1.6M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | 28.77 | ★ 79.02 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $243,180,000.00 | $53,426,000.00 |
| Revenue This Year | $3.12 | $143.48 |
| Revenue Next Year | $3.42 | $25.40 |
| P/E Ratio | $5.69 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $10.16 | $0.46 |
| 52 Week High | $18.13 | $3.07 |
| Indicator | OSPN | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 51.65 |
| Support Level | $10.26 | $1.41 |
| Resistance Level | $11.68 | $2.01 |
| Average True Range (ATR) | 0.41 | 0.11 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 31.75 | 57.32 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.